BPTH Bio-Path Holdings Inc
18,628
$2.72
$0.09
(3.20%)
| Watchers | 18,628 |
| 52-Wk Low | $2.35 |
| 52-Wk High | $44.80 |
| Market Cap | $4.26M |
| Volume | 32,552.00 |
| 52-Wk High | $44.80 |
| 52-Wk Low | $2.35 |
Why Bio-Path Stock Is SoaringBenzinga • 22 days ago
Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to...
Share to Feed
Clinical Advances Across Multiple Programs with Several MilestonesHOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its...
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q4 2023...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize...
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a...
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the Company ), a...
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline TherapyHOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings...